Skip to main content
Premium Trial:

Request an Annual Quote

BG Medicine Fails to Meet Listing Requirement, Nasdaq Warns Firm

NEW YORK (GenomeWeb News) – BG Medicine said late on Friday it has been notified by Nasdaq for the second time in less than six months that it does not fulfill a requirement for continued listing on the exchange.

In a document filed with the US Securities and Exchange Commission, the Waltham, Mass.-based company said that it received written notice from the Listing Qualifications Department of Nasdaq on May 14 warning that for the preceding 30 consecutive business days, it had closed below the $50 million minimum market value required for listed securities to remain listed on the Nasdaq Global Market.

BG Medicine has 180 calendar days, or until Nov. 11, to regain compliance by closing at or above the $50 million limit for at least 10 consecutive business day during the 180-day grace period. If BG Medicine does not regain compliance by Nov. 11, it will be subject to delisting. The company can then appeal the Nasdaq staff's determination to a Nasdaq Listing Qualifications Panel and request a hearing.

BG Medicine said it is considering its options to regain compliance for listing on the Nasdaq Global Market. It added that it may also transfer its listing to the Nasdaq Capital Market, which has lower listing requirements, including a minimum $35 million market value for listed securities.

In late December, the company was similarly notified by Nasdaq that it did not meet the requirement for the minimum market value. It regained compliance shortly afterward, however.

BG Medicine recently reported that its first-quarter revenues spiked 88 percent year over year. It also named Paul Sohmer as its new CEO.

In afternoon trading, shares of the company were flat at $1.69

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.